Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
Brock Binkowski, Sauk City, WI (US); Lance P. Encell, Fitchburg, WI (US); Mary Hall, Waunakee, WI (US); Matthew B. Robers, Madison, WI (US); Michael R. Slater, Madison, WI (US); Keith V. Wood, Mount Horeb, WI (US); and Monika G. Wood, Mount Horeb, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on May 27, 2021, as Appl. No. 17/332,459.
Application 14/160,282 is a division of application No. 13/287,986, filed on Nov. 2, 2011, granted, now 8,669,103, issued on Mar. 11, 2014.
Application 17/332,459 is a continuation of application No. 17/011,597, filed on Sep. 3, 2020, granted, now 11,661,623.
Application 17/011,597 is a continuation of application No. 15/948,070, filed on Apr. 9, 2018, granted, now 10,774,364, issued on Sep. 15, 2020.
Application 15/948,070 is a continuation of application No. 14/160,282, filed on Jan. 21, 2014, granted, now 9,951,373, issued on Apr. 24, 2018.
Claims priority of provisional application 61/409,422, filed on Nov. 2, 2010.
Prior Publication US 2022/0348983 A1, Nov. 3, 2022
1. A composition comprising a circularly permuted polypeptide having an N-terminal segment linked to a C-terminal segment, wherein the N-terminal segment of the circularly permuted polypeptide has at least 96% sequence identity to a portion of SEQ ID NO: 89 from a circular permutation site to the C-terminus of SEQ ID NO: 89, wherein the C-terminal segment of the circularly permuted polypeptide has at least 96% sequence identity to a portion of SEQ ID NO: 89 from the N-terminus to the circular permutation site of SEQ ID NO: 89, wherein the circular permutation site is at a position corresponding to one of positions 27, 122, 147, and 157 of SEQ ID NO: 89, and wherein the circularly permuted polypeptide exhibits luciferase activity in the presence of a coelenterazine substrate.